1 / 1

Global Lipid Regulator Sales Dynamics: Generic vs. Non-Generic Products

Lipid regulator market shifts post-Lipitor's US patent expiry. Non-generics face challenge from low-price generics. Former dominance wanes post-2006 wave of protection expiry. Analysis based on IMS MIDAS data.

edie
Download Presentation

Global Lipid Regulator Sales Dynamics: Generic vs. Non-Generic Products

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Non-generic products still claim a large share of lipid regulator sales, but almost half of volume is generic Since 2006, when a of wave protection expiries of major brands in the statins class started, low-price generics have claimed a large share of volume. And although brands (non-generic products) still make up most of value sales, Lipitor’s recent protection expiry in the US is likely to change that balance. Lipid Regulators Global Sales and Volume, 2001-2011 VOLUME (STANDARD UNITS BN) SALES (US$BN) OTHER PRODUCTS NON CATEGORIZED PRODUCTS GENERIC PRODUCTS NON GENERIC PRODUCTS Source: IMS MIDAS®, December2011 INFOGRAFIK 06_2/2012

More Related